Gan, Li-Ming http://orcid.org/0000-0003-2933-1404
Lagerström-Fermér, Maria
Carlsson, Leif G.
Arfvidsson, Cecilia
Egnell, Ann-Charlotte
Rudvik, Anna
Kjaer, Magnus
Collén, Anna
Thompson, James D.
Joyal, John
Chialda, Ligia
Koernicke, Thomas
Fuhr, Rainard
Chien, Kenneth R.
Fritsche-Danielson, Regina
Article History
Received: 23 October 2018
Accepted: 4 February 2019
First Online: 20 February 2019
Competing interests
: This study was funded by AstraZeneca. AstraZeneca develops and markets treatments for cardiovascular and metabolic disorders. AZD8601 (VEGF-A-modified mRNA) is an investigational medicinal product with no approved indication. L.-M.G., M.L.-F., L.G.C., C.A., A.-C.E., A.R., M.K., A.C. and R.F.-D. are employees of AstraZeneca and may own stock or stock options. J.D.T. and J.J. are employees of Moderna, Inc., and may own stock or stock options. L.C., T.K., and R.F. are current or former employees of PAREXEL. AstraZeneca provided funding to PAREXEL for conducting this study. K.R.C. is an advisor and chair of the External Science Panel for AstraZeneca and a member of the Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Center in Huddinge, and receives support for these services, as well as research support through the Karolinska Institutet Center. He is also a co-founder and equity holder of Moderna, Inc.